X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
teneligliptin (91) 91
index medicus (43) 43
type 2 diabetes (36) 36
humans (35) 35
diabetes (34) 34
pharmacology & pharmacy (29) 29
diabetes mellitus, type 2 - drug therapy (27) 27
dipeptidyl peptidase-4 inhibitor (26) 26
glucose (26) 26
male (26) 26
dpp-4 inhibitor (24) 24
endocrinology & metabolism (23) 23
sitagliptin (22) 22
metformin (21) 21
diabetes mellitus (20) 20
middle aged (20) 20
dipeptidyl-peptidase iv inhibitors - therapeutic use (19) 19
pyrazoles - therapeutic use (19) 19
thiazolidines - therapeutic use (19) 19
female (18) 18
dipeptidyl peptidase-4 inhibitors (17) 17
aged (16) 16
double-blind (15) 15
hypoglycemic agents (15) 15
hypoglycemic agents - therapeutic use (15) 15
pyrazoles - adverse effects (14) 14
safety (14) 14
thiazolidines - adverse effects (14) 14
type 2 diabetes mellitus (14) 14
japanese patients (13) 13
mellitus (13) 13
dipeptidyl-peptidase iv inhibitors - administration & dosage (12) 12
dipeptidyl-peptidase iv inhibitors - adverse effects (12) 12
glucagon-like peptide-1 (12) 12
glycemic control (12) 12
hypoglycemia (12) 12
pyrazoles - administration & dosage (12) 12
thiazolidines - administration & dosage (12) 12
vildagliptin (12) 12
diabetes mellitus, type 2 - blood (11) 11
drug therapy (11) 11
drug therapy, combination (11) 11
insulin (11) 11
original article (11) 11
adult (10) 10
animals (10) 10
dextrose (10) 10
diabetes therapy (10) 10
dipeptidyl-peptidase iv inhibitors - pharmacology (10) 10
glycosylated hemoglobin (10) 10
hemoglobin (10) 10
original (10) 10
pharmacokinetics (10) 10
clinical trials (9) 9
efficacy (9) 9
hemodialysis (9) 9
hyperglycemia (9) 9
linagliptin (9) 9
peptidase (9) 9
treatment outcome (9) 9
canagliflozin (8) 8
care and treatment (8) 8
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (8) 8
double-blind method (8) 8
glycated hemoglobin a - analysis (8) 8
hypoglycemic agents - administration & dosage (8) 8
hypoglycemic agents - adverse effects (8) 8
metaanalysis (8) 8
oxidative stress (8) 8
pyrazoles - pharmacokinetics (8) 8
pyrazoles - pharmacology (8) 8
saxagliptin (8) 8
thiazolidines - pharmacokinetics (8) 8
thiazolidines - pharmacology (8) 8
analysis (7) 7
blood glucose - drug effects (7) 7
dpp-4 inhibitors (7) 7
drug dosages (7) 7
endocrinology (7) 7
fasting (7) 7
hypoglycemia - chemically induced (7) 7
internal medicine (7) 7
japan (7) 7
medicine & public health (7) 7
original research (7) 7
patients (7) 7
placebo-controlled trial (7) 7
alogliptin (6) 6
blood glucose - metabolism (6) 6
chemistry, analytical (6) 6
combination (6) 6
combination therapy (6) 6
dpp (6) 6
drug administration schedule (6) 6
endocrine system diseases (6) 6
hba1c (6) 6
metabolism (6) 6
patient outcomes (6) 6
therapy (6) 6
type-2 diabetes-mellitus (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 10, pp. 8898 - 8910
High-glucose-induced oxidative stress contributes to cardiovascular endothelial damage in diabetes. Glucagon-like peptide 1 (GLP-1) is beneficial to... 
CVD | GLP-1 | DPP-4i | Teneligliptin | High glucose
Journal Article
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, ISSN 1178-7007, 2019, Volume 12, pp. 961 - 967
Background: Newer therapies, such as dipeptidyl peptidase-IV inhibitors, are increasingly being used in the treatment of type 2 diabetes mellitus (T2DM).... 
QT prolongation | INHIBITOR | diabetes | ENDOCRINOLOGY & METABOLISM | teneligliptin | Teneligliptin | Diabetes | QT Prolongation
Journal Article
Journal of Diabetes Science and Technology, ISSN 1932-2968, 3/2019, Volume 13, Issue 2, pp. 413 - 414
Journal Article
Postgraduate Medical Journal, ISSN 0032-5473, 11/2018, Volume 94, Issue 1117, pp. 662 - 663
Correspondence to Professor Davinder Parsad, Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research,... 
bullous pemphigoid | diabetic male | blisters | teneligliptin | MEDICINE, GENERAL & INTERNAL | Hemoglobin | Diabetes | Dermatology | Older people
Journal Article
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, ISSN 1178-7007, 06/2019, Volume 12, pp. 961 - 967
Background: Newer therapies, such as dipeptidyl peptidase-IV inhibitors, are increasingly being used in the treatment of type 2 diabetes mellitus (T2DM).... 
Studies | Clinical trials | Hyperglycemia | Diabetes | Clinical medicine | Drug dosages
Journal Article
Biopharmaceutics & Drug Disposition, ISSN 0142-2782, 04/2016, Volume 37, Issue 3, pp. 142 - 155
The tissue distribution of teneligliptin, a dipeptidyl peptidase (DPP)‐4 inhibitor, was investigated in rats, and compared with tissue distributions previously... 
DPP‐4 inhibitor | tissue distribution | teneligliptin | DPP-4 inhibitor | Original Paper | Original Papers
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 333 - 347
Type 2 diabetes ( T2DM ) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long... 
linagliptin | glyburide | incretin | saxagliptin | diabetes mellitus | GLP | omarigliptin | anagliptin | gliclazide | glimepiride | sitagliptin | vildagliptin | gemigliptin | alogliptin | antidiabetic drug | glipizide | glycaemic control | trelagliptin | glibenclamide | evogliptin | teneligliptin | Glimepiride | Incretin | GLP-1 | Trelagliptin | Diabetes mellitus | Sitagliptin | Glipizide | Evogliptin | Anagliptin | Glyburide | Antidiabetic drug | Omarigliptin | Gliclazide | Alogliptin | Linagliptin | Vildagliptin | Gemigliptin | Glibenclamide | Glycaemic control | Teneligliptin | Saxagliptin | SEVERE HYPOGLYCEMIA | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS | INSULIN SECRETAGOGUES | GLYCEMIC CONTROL | CARDIOVASCULAR EVENTS | DPP-4 INHIBITOR | DOUBLE-BLIND | METFORMIN THERAPY | SAVOR-TIMI 53 | Glycated Hemoglobin A - analysis | Hypoglycemia - epidemiology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Risk | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Weight Gain - drug effects | Sulfonylurea Compounds - administration & dosage | Diabetic Angiopathies - prevention & control | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Sulfonylurea Compounds - therapeutic use | Sulfonylurea Compounds - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Diabetes Mellitus, Type 2 - blood | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Diabetic Cardiomyopathies - epidemiology | Diabetic Angiopathies - epidemiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Prescription drugs | Insulin | Side effects | Peptidase | Clinical trials | Metformin | Hypoglycemia | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Patients
Journal Article
International Journal of General Medicine, ISSN 1178-7074, 04/2016, Volume 2016, Issue Issue 1, pp. 65 - 71
Yoshinori Okuda,1 Seitaro Omoto,2 Takehito Taniura,3 Akira Shouzu,4 Shosaku Nomura,51Division of Internal Medicine, Meisei Memorial Hospital, 2Division of... 
PDMP | type 2 diabetes mellitus | hemodialysis | PAI-1 | teneligliptin
Journal Article
Analytical Chemistry Letters, ISSN 2229-7928, 07/2017, Volume 7, Issue 4, pp. 556 - 566
A simple, accurate, precise and economical HPTLC and UV method has been developed and validated for the estimation of teneligliptin hydrobromide hydrate (THH)... 
forced degradation | Teneligliptin hydrobromide | spectroscopic method | validation | HPTLC
Journal Article
International Journal of Green Pharmacy, ISSN 0973-8258, 07/2018, Volume 12, Issue 3, pp. S670 - S674
Introduction: Teneligliptin (TGP) is an oral dipeptidyl peptidase inhibitor used for the treatment of type 2 diabetes mellitus. A simple liquid chromatographic... 
Validation | Reversed-phase high-performance liquid chromatography | Isocratic mode | Eplerenone | Teneligliptin | Chromatography | Inhibitor drugs | Diabetes
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2014, Volume 16, Issue 5, pp. 418 - 425
Aims To assess the efficacy and safety of teneligliptin in combination with glimepiride in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately... 
DPP | type 2 diabetes mellitus | HbA1c | Japanese | 4 inhibitor | glimepiride | teneligliptin | Glimepiride | Type 2 diabetes mellitus | DPP-4 inhibitor | Teneligliptin | THERAPY | GLUCAGON-LIKE PEPTIDE-1 | SULFONYLUREAS | GLUCOSE | ENDOCRINOLOGY & METABOLISM | INHIBITORS | DIPEPTIDYL PEPTIDASE-IV | Japan - epidemiology | Hypoglycemia - epidemiology | Pyrazoles - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Postprandial Period | Adult | Hypoglycemia - blood | Drug Therapy, Combination | Hypoglycemia - chemically induced | Pyrazoles - adverse effects | Hypoglycemic Agents - therapeutic use | Thiazolidines - adverse effects | Fasting | Double-Blind Method | Drug Administration Schedule | Sulfonylurea Compounds - therapeutic use | Treatment Outcome | Thiazolidines - therapeutic use | Blood Glucose - drug effects | Asian Continental Ancestry Group | Diabetes Mellitus, Type 2 - blood | Pyrazoles - administration & dosage | Aged | Thiazolidines - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Hemoglobin | Glucose metabolism | Blood sugar | Diabetes therapy
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.